{"id":390418,"date":"2019-05-18T00:00:00","date_gmt":"2019-05-18T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfop0001-2019-biopharma-age-related-macular-degeneration-disease-landscape-and-forecast-g7-2019\/"},"modified":"2026-04-18T23:24:23","modified_gmt":"2026-04-18T23:24:23","slug":"dlsfop0001-2019-biopharma-age-related-macular-degeneration-disease-landscape-and-forecast-g7-2019","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfop0001-2019-biopharma-age-related-macular-degeneration-disease-landscape-and-forecast-g7-2019\/","title":{"rendered":"Age-Related Macular Degeneration | Disease Landscape and Forecast | G7 | 2019"},"content":{"rendered":"<p>The wet\u00a0<abbr title=\"age-related macular degeneration\">AMD<\/abbr>\u00a0market is dominated by three therapies\u2014Roche \/ Genentech \/ Novartis\u2019s Lucentis, approved for wet\u00a0<abbr title=\"age-related macular degeneration\">AMD<\/abbr>, Roche \/ Genentech \/ Chugai\u2019s Avastin, approved for cancer but commonly compounded and used off-label for wet\u00a0<abbr title=\"age-related macular degeneration\">AMD<\/abbr>, and Regeneron \/ Bayer HealthCare \/ Santen\u2019s Eylea, which has experienced strong and continued uptake at the expense of the other\u00a0<abbr title=\"vascular endothelial growth factor\">VEGF<\/abbr>\u00a0inhibitors. Although the majority of\u00a0<abbr title=\"age-related macular degeneration\">AMD<\/abbr>\u00a0patients are diagnosed with the dry form of\u00a0<abbr title=\"age-related macular degeneration\">AMD<\/abbr>, management of this disease type is limited to minimally effective vitamin formulations because no prescription pharmacotherapies are approved for this large and underserved subpopulation. While the bulk of emerging therapies target wet\u00a0<abbr title=\"age-related macular degeneration\">AMD<\/abbr>\u00a0patients because the pathology presents clearer drug targets, there are a small number of novel therapies being tested in patients with the dry form of\u00a0<abbr title=\"age-related macular degeneration\">AMD<\/abbr>\u2014an indication that has been plagued by several Phase III failures.<\/p>\n<p><strong>Questions Answered:<\/strong><\/p>\n<ul>\n<li>Do\u00a0<abbr title=\"key opinion leader\">KOL<\/abbr>s perceive any differences between the mainstays Avastin, Eylea, and Lucentis? How is their use expected to change, if at all, over the next ten years?<\/li>\n<li>Biosimilar versions of Eylea and Lucentis are forecast to launch within the next five years. What is the likely impact of these therapies on current and emerging\u00a0<abbr title=\"vascular endothelial growth factor\">VEGF<\/abbr>\u00a0inhibitors?<\/li>\n<li>A substantial unmet need in wet\u00a0<abbr title=\"age-related macular degeneration\">AMD\u00a0<\/abbr>exists for therapies with longer dosing intervals than offered by current therapies. To what extent are the new and emerging\u00a0<abbr title=\"vascular endothelial growth factor\">VEGF<\/abbr>\u00a0inhibitors brolucizumab (Beovu; Novartis), abicipar pegol (Allergan), the ranibizumab port delivery system (Roche), and conbercept (Chengdu Kanghong Biotech) as well as\u00a0the emerging\u00a0<abbr title=\"vascular endothelial growth factor\">VEGF<\/abbr>\u00a0\/\u00a0<abbr title=\"angiopoietin-2\">Ang-2<\/abbr>\u00a0inhibitor faricimab (Roche) expected to capitalize on this unmet need?<\/li>\n<\/ul>\n<p><strong>Product Description:<\/strong><\/p>\n<p><em>Disease Landscape &#038; Forecast<\/em>\u00a0provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.<\/p>\n<p><b>Markets covered:<\/b>\u00a0United States, France, Germany, Italy, Spain, United Kingdom, and Japan.<\/p>\n<p><strong>Primary research:\u00a0<\/strong>18 country-specific interviews with thought-leading retinal specialists. Supported by survey data collected for this and other\u00a0<abbr title=\"Decision Resources Group\">DRG<\/abbr>\u00a0research.<\/p>\n<p><strong>Epidemiology:<\/strong>\u00a0Total prevalence of late\u00a0<abbr title=\"age-related macular degeneration\">AMD<\/abbr>\u00a0by country, segmented by\u00a0<abbr title=\"geographic atrophy\">GA<\/abbr>\u00a0and wet\u00a0<abbr title=\"age-related macular degeneration\">AMD<\/abbr>\u00a0subpopulations, including diagnosed and drug-treated rates.<\/p>\n<p><strong>Forecast:<\/strong>\u00a0Ten-year, annualized, drug-level sales and patient share of key\u00a0<abbr title=\"geographic atrophy\">GA<\/abbr>\u00a0and wet\u00a0<abbr title=\"age-related macular degeneration\">AMD<\/abbr>\u00a0therapies, segmented by brands \/ biosimilars and epidemiological subpopulations.<\/p>\n<p><strong>Emerging therapies:\u00a0<\/strong>Phase III\/<abbr title=\"preregistered\">PR<\/abbr>: 7 drugs; Phase II\/III: 1 drug; key early-phase therapies.<\/p>\n","protected":false},"template":"","class_list":["post-390418","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-age-related-macular-degeneration","biopharma-date-931"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390418","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390418\/revisions"}],"predecessor-version":[{"id":576635,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390418\/revisions\/576635"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390418"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}